Phase 1/2 × Recruiting × Neoplasms, Germ Cell and Embryonal × Clear all
NCT05092451 2026-03-18

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
80 enrolled
NCT03093116 2025-07-10

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA